


Product Name : ACBI3
Cat. No. : PC-21662
CAS No. : 2938169-76-5
Molecular Formula : C₅₀H₆₂N₁₄O₆S₂
Molecular Weight : 1019.26
Target : PROTAC
Solubility : 10 mM in DMSO



CAS: 2938169-76-5

Biological Activity

ACBI3 is a selective, potent and in vivo active **pan-KRAS PROTAC** degrader, potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles (DC50=3.9 nM in GP2d cells).

ACBI3 exhibits potent intracellular VHL engagement, ternary complex formation and ubiquitination translating into overall E3-ligase dependent cellular degradation potency.

ACBI3 is broadly active on cancer cell lines bearing KRAS mutations vs KRAS WT cell lines (IC₅₀, 478 nM vs 8.3 μM, respectively).

ACBI3 (30 mg/kg, daily s.c.) resulted in pronounced tumour regressions with a tumour growth inhibition of 127% in GP2d tumour bearing mice.

ACBI3 effectively acts on the majority of KRAS mutants with high prevalence in cancer patients, and as a result potently inhibit proliferation in KRAS mutant cell lines covering a wide range of tumour types.

References

Johannes Popow, et al. Targeting cancer with small molecule pan-KRAS degraders. bioRxiv October 26, 2023.

Patent WO2023099620 A1.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com